CTAP (TFA)

• UNSPSC Description:

  CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction[1][2].

• Target Antigen:

  Opioid Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/ctap-tfa.html

• Purity:

  99.56

• Solubility:

  H2O : 100 mg/mL (ultrasonic)

• Smiles:

  OC(C(F)(F)F)=O.O=C([C@@H](NC([C@H](CSSC(C)([C@H](NC([C@](NC([C@@H](NC1=O)CCCNC(N)=N)=O)([H])[C@H](O)C)=O)C(N[C@H](C(N)=O)[C@H](O)C)=O)C)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=C(C=C3)O)N[C@@H]1CC4=CNC5=CC=CC=C45

• Molecular Weight:

  1218.32

• References & Citations:

  [1]Mitchell J Bartlett, et al. Highly-selective µ-opioid Receptor Antagonism Does Not Block L-DOPA-induced Dyskinesia in a Rodent Model.BMC Res Notes|[2]Abbruscato TJ, et al. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther. 1997 Jan;280(1):402-9.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Clinical Information:

  No Development Reported